FilingReader Intelligence
Jumpcan Pharmaceutical receives drug approval amid takeover bid
July 11, 2025 at 08:49 AM UTC•By FilingReader AI
Hubei Jumpcan Pharmaceutical's subsidiary received drug registration certificates for Compound Polyethylene Glycol Electrolyte Powder, expanding its product line.
Concurrently, Cao Fei is making a tender offer for 350.8 million shares at 24.85 yuan per share, representing 38.06% of total share capital. As of July 10, 2025, 4,100 shares have been pre-accepted.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:600566•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Hubei Jumpcan Pharmaceutical publishes news
Free account required • Unsubscribe anytime